Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:NGM

NGM Biopharmaceuticals (NGM) Stock Price, News & Analysis

NGM Biopharmaceuticals logo

About NGM Biopharmaceuticals Stock (NASDAQ:NGM)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$1.54
$1.57
50-Day Range
$1.52
$1.63
52-Week Range
$0.60
$4.69
Volume
2.39 million shs
Average Volume
1.47 million shs
Market Capitalization
$128.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company develops NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced metastatic solid tumors; and Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of primary sclerosing cholangitis and non-alcoholic steatohepatitis. It also develops NGM120, an GFRAL antagonist antibody, which is in Phase II clinical trial to treat hyperemesis gravidarum; NGM831 and NGM438 which is in phase I/II clinical trial for the treatment of advanced solid tumors; and NGM621, an monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck to focus primarily on the identification, research and development of collaboration compounds directed to targets in the fields of ophthalmology and cardiovascular or metabolic, or CVM, disease, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.

Remove Ads
Receive NGM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NGM Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

NGM Stock News Headlines

Here’s How to Claim Your Stake in Elon’s Private Company, xAI
Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.
See More Headlines

NGM Stock Analysis - Frequently Asked Questions

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) released its earnings results on Thursday, November, 4th. The company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by $0.03. The business had revenue of $18.58 million for the quarter, compared to the consensus estimate of $18.90 million. NGM Biopharmaceuticals had a negative net margin of 3,223.34% and a negative trailing twelve-month return on equity of 77.85%.

NGM Biopharmaceuticals (NGM) raised $100 million in an initial public offering on Thursday, April 4th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Cowen served as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that NGM Biopharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Adobe (ADBE), Advanced Micro Devices (AMD), Broadcom (AVGO), CymaBay Therapeutics (CBAY) and PayPal (PYPL).

Company Calendar

Last Earnings
11/04/2021
Today
4/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:NGM
Fax
N/A
Employees
138
Year Founded
1998

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-142,380,000.00
Net Margins
-3,223.34%
Pretax Margin
-3,223.34%

Debt

Sales & Book Value

Annual Sales
$4.42 million
Price / Cash Flow
N/A
Book Value
$1.80 per share
Price / Book
0.86

Miscellaneous

Free Float
53,499,000
Market Cap
$128.53 million
Optionable
Optionable
Beta
1.27

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:NGM) was last updated on 4/2/2025 by MarketBeat.com Staff
From Our Partners